logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2019 – Gilteritinib, a new treatment paradigm for relapsed/refractory acute myeloid leukaemia

The final results of the ADMIRAL trial highlight the value of gilteritinib monotherapy for adult patients harbouring FLT3-mutations